Atogepant improved measures of functioning using AIM-D and HIT-6 in a 12-week phase 3 trial for migraine prevention

Authors
Category Primary study
ConferenceEuropean Journal of Neurology
Year 2021
This article has no abstract
Epistemonikos ID: 6ff75c0f96128637db1b038692d38a6b7cb0d7bc
First added on: Apr 30, 2026